Toviaz
Product Images NDC 69189-0242

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Toviaz (NDC 69189-0242). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fesoterodine Er 4 mg Tablet Label (6918902421)

Label for Toviaz 4 mg tablet containing fesoterodine fumarate ER. The label shows manufacturer Pfizer, hospital lot number, expiration date 10/04/2016, and the NDC 69189-0242. The label also indicates it is from Avera McKennan in Sioux Falls, SD.*

FDA Label Image

Chemical Structure (Toviaz 01)

Chemical structure diagram of the active ingredient in Toviaz, showing the molecular components and arrangement, including an aromatic ring, ester groups, and quaternary ammonium moiety, alongside an associated acid molecule.*

FDA Label Image

Figure 1 (Toviaz 02)

A line graph titled 'Change in Number of Micturitions per 24 h (Study 1)' showing mean change from baseline in number of micturitions over 12 weeks for placebo, Toviaz 4 mg, and Toviaz 8 mg groups. The x-axis represents time in weeks (0 to 12), and the y-axis shows mean change from baseline (number of micturitions per 24 hours) ranging from 0 to -3. The graph displays three lines: placebo (dotted line), Toviaz 4 mg (dashed line), and Toviaz 8 mg (solid line), illustrating a greater reduction in micturitions for Toviaz groups compared to placebo over time.*

FDA Label Image

Figure 2 (Toviaz 03)

A line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 1)' showing mean changes from baseline over 12 weeks. It compares placebo (dotted line with circles), Toviaz 4 mg (dashed line with triangles), and Toviaz 8 mg (solid line with squares). The Toviaz groups demonstrate greater reductions in urge incontinence episodes per 24 hours compared to placebo over time.*

FDA Label Image

Figure 3 (Toviaz 04)

Line graph showing the change in number of micturitions per 24 hours over 12 weeks in Study 2 for Toviaz 4 mg, Toviaz 8 mg, and placebo groups. The y-axis shows mean change from baseline, with both Toviaz doses showing greater reduction compared to placebo over time.*

FDA Label Image

Figure 4 (Toviaz 05)

A line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 2)' showing mean change from baseline over 12 weeks. The x-axis represents time in weeks (0 to 12) and the y-axis shows mean change from baseline in urge incontinence episodes per 24 hours. It compares Placebo (dotted line), Toviaz 4 mg (dashed line), and Toviaz 8 mg (solid line) groups, with Toviaz 8 mg showing the greatest reduction in episodes over time.*

FDA Label Image

Logo (Toviaz 06)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.